Pei Hui, PhD, MD
Professor of Pathology and of Obstetrics, Gynecology and Reproductive SciencesCards
About
Research
Overview
Medical Research Interests
Academic Achievements & Community Involvement
Clinical Care
Overview
Pei Hui, MD, PhD, is a pathologist who specializes in gynecological diseases and cancers, including endometrial, ovarian, and fallopian tube cancers.
“You understand disease better through pathology,” Dr. Hui says. “You learn how it develops and its mechanisms at a cellular and molecular level.”
Dr. Hui points out that although pathologists rarely see patients face-to-face, they are still in charge of the well-being of the patient through the microscopic diagnosis. “We look at 30 to 50 cases each day, so in a way you could say that we see more patients than any other physician,” he says.
Dr. Hui says that he enjoys working as a team to provide better care for patients. For example, on any given day, he might be talking via phone, email, or text, to a patient’s oncologist or doctor. “We are informative for them because we provide timely and accurate diagnosis and using new biomarkers that may change the patient treatment options. The boundary between physician and pathologist is smaller than ever.”
What most excites Dr. Hui is the ability to improve diagnostic accuracy and find new biomarkers to guide clinical management for patients and prognosis. He continues his research in that area as professor and director of gynecologic pathology at Yale School of Medicine.
Clinical Specialties
Fact Sheets
Molecular Diagnostics
Learn More on Yale Medicine
Board Certifications
Molecular Genetic Pathology
- Certification Organization
- AB of Pathology
- Original Certification Date
- 2003
Anatomic & Clinical Pathology
- Certification Organization
- AB of Pathology
- Original Certification Date
- 2000
News & Links
Media
- Acquisition of global imprinting alteration at a critical time point in a preimplantation embryo occurs through the de novo absence of the maternal haploid genome in sporadic androgenetic complete hydatidiform moles (CHMs) or through mutations of NLRP7 or KHDC3L shutting down the entire maternal imprinting gene expression in familial biparental CHMs (from Annu. Rev. Pathol. Mech. Dis. 2017. 12:449–85).
- Atypical placental site nodule (APSN). As a precursor lesion to epithelioid trophoblastic tumor, APSN has morphologic features, including larger size of greater than 5 mm (A), increased cellularity (B and C), marked nuclear atypia (C and D), increased mitotic activity (D, arrows), and increased Ki-67 proliferation index to 8%to 10% (E and F) (hematoxylin-eosin, original magnifications320 [A],3100 [B and E], and3400 [C and D]; Ki-67, original magnification3100 [F] (from Arch Pathol Lab Med. 2018 Nov 8; 2018 Nov 8. PMID: 30407075)
- Microsatellite instability testing by analysis of PCR products amplified at 5 NCI recommended loci. a: Minimal microsatellite shift at four of 5 microsatellite loci (red arrows) in an endometrial endometrioid adenocarcinoma. b: Major microsatellite shifts (blue arrows) and minimal microsatellite shifts (red arrow) in a colorectal carcinoma). (From Mod Pathol. 2018 Nov 15; 2018 Nov 15. PMID: 30443012)
- DNA mismatch repair mechanism. MLH1 dimerizes with PMS2, PMS1 or MLH3 to form MutLα, MutLβ or MutLγ heterodimer, respectively. MSH2 dimerizes with MSH6 or MSH3 to form MutSα or MutSβ heterodimer respectively, with the main function of binding DNA helix and recognizing DNA mismatches. Working together with the MutL complexes, the MSH2/MSH6 (MutSα) complex guides the repair of single base mismatch and small loop mismatch, whereas the MSH2/MSH3 (MutSβ) complex guides the repair of small to large loop mismatch (Expert Review Of Molecular Diagnostics 2016, 16:591-604. 2016).
News
- November 07, 2024
Yale Ob/Gyn Faculty Present the Latest in Gynecologic Oncology at Memorial Conference
- July 01, 2024
Pei Hui, MD, PhD, Chosen as President-Elect of International Society of Gynecological Pathologists
- April 15, 2024
Genetic Analysis of Rare, Often Deadly Cervical Cancer Uncovers Potential Treatments
- April 09, 2024
Topical Shows Promise in Treating Precancerous Cervical Condition